Neoadjuvant Immunotherapy and Chemotherapy for Head and Neck Cancer
Author Information
Author(s): Sun Ying, Yang Guanghui, Sun Ruijie, Cao Fangli
Primary Institution: Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China
Hypothesis
Can neoadjuvant immunotherapy combined with chemotherapy improve outcomes in patients with head and neck squamous cell carcinoma?
Conclusion
The combination of nivolumab and chemotherapy resulted in significant tumor regression and improved immune response in a patient with head and neck squamous cell carcinoma.
Supporting Evidence
- The patient achieved significant tumor regression and major pathological response without severe adverse events.
- Post-treatment analyses revealed increased PD-L1 expression and improved CD8+ lymphocyte infiltration.
Takeaway
A patient with head and neck cancer got a special treatment that combined two types of medicine, and it helped shrink the tumor a lot.
Methodology
The patient received neoadjuvant nivolumab plus nab-paclitaxel and carboplatin, with tumor biomarkers assessed by immunohistochemistry and apoptosis-related molecules analyzed via Western blotting.
Limitations
Findings are based on a single case, limiting generalizability.
Participant Demographics
68-year-old Asian male with a history of hypertension and diabetes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website